Literature DB >> 25677258

Serological surveillance for Penicillium marneffei infection in HIV-infected patients during 2004-2011 in Guangzhou, China.

Y-F Wang1, H-F Xu2, Z-G Han2, L Zeng1, C-Y Liang2, X-J Chen1, Y-J Chen1, J-P Cai3, W Hao1, J F-W Chan4, M Wang5, N Fu6, X-Y Che1.   

Abstract

Prevalence of disseminated Penicillium marneffei infection is not known in human immunodeficiency virus (HIV)-infected patients. This retrospective study aimed to evaluate the prevalence of and risk factors for disseminated P. marneffei infection in HIV-infected patients during 2004-11 in Guangzhou, China. We tested 8131 archived HIV-infected patient serum samples for P. marneffei-specific mannoprotein (Mp1p) antigen using a highly sensitive and specific ELISA that we previously established. The CD4 count of 2686 cases was determined by flow cytometry. Logistic regression was used to assess predictors of Mp1p antigenaemia. The overall prevalence of disseminated penicilliosis as detected by positive serum Mp1p antigen was 9.36% (761/8131), in good concordance with Platelia™ Aspergillus immunoassay. During 2004-11, the prevalence increased to a peak of 12.58% (158/1256) in 2010 and decreased in 2011. Penicilliosis was strongly associated with progression from HIV to AIDS (OR 4.66, 95% CI 3.94-5.51, p <0.001) and humidity (OR 1.02, 95% CI 1.01-1.03, p 0.002). Disseminated penicilliosis occurred mainly during the rainy seasons (p <0.001). For 2686 cases with known CD4 count, logistic regression showed that CD4 count of <200 cells/μL was a risk factor for penicilliosis (OR 2.90, 95% CI 1.10-7.66, p 0.032), especially when it was <50 cells/μL (OR 24.26, 95% CI 10.63-55.36, p <0.001) during which 28.06% of patients developed disseminated penicilliosis. In conclusion, approximately 9.36% of the HIV-infected patients in our study developed disseminated penicilliosis. Rapid diagnosis may be achieved by performing serological surveillance for Mp1p antigenaemia as a routine procedure for all HIV-infected patients with CD4 count of <50 cells/μL.
Copyright © 2014 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AIDS; HIV; Mp1p; Penicillium marneffei; penicilliosis

Mesh:

Substances:

Year:  2014        PMID: 25677258     DOI: 10.1016/j.cmi.2014.12.014

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  12 in total

1.  Clinical epidemiology and outcome of HIV-associated talaromycosis in Guangdong, China, during 2011-2017.

Authors:  R S Ying; T Le; W P Cai; Y R Li; C B Luo; Y Cao; C Y Wen; S G Wang; X Ou; W S Chen; S Z Chen; P L Guo; M Chen; Y Guo; X P Tang; L H Li
Journal:  HIV Med       Date:  2020-12       Impact factor: 3.180

2.  Clinical Characteristics and Prognosis of Penicilliosis Among Human Immunodeficiency Virus-Infected Patients in Eastern China.

Authors:  Jun Chen; Renfang Zhang; Yinzhong Shen; Li Liu; Tangkai Qi; Zhenyan Wang; Wei Song; Yang Tang; Hongzhou Lu
Journal:  Am J Trop Med Hyg       Date:  2017-06       Impact factor: 2.345

Review 3.  Talaromycosis (Penicilliosis) Due to Talaromyces (Penicillium) marneffei: Insights into the Clinical Trends of a Major Fungal Disease 60 Years After the Discovery of the Pathogen.

Authors:  Cunwei Cao; Liyan Xi; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2019-12       Impact factor: 2.574

Review 4.  Opportunistic Invasive Mycoses in AIDS: Cryptococcosis, Histoplasmosis, Coccidiodomycosis, and Talaromycosis.

Authors:  Daniel B Chastain; Andrés F Henao-Martínez; Carlos Franco-Paredes
Journal:  Curr Infect Dis Rep       Date:  2017-08-22       Impact factor: 3.663

5.  T. marneffei infection complications in an HIV-negative patient with pre-existing pulmonary sarcoidosis: a rare case report.

Authors:  Xiaoming Yu; Keji Miao; Changsheng Zhou; Yuelin Cai; Xiaoying Huang; Yanfan Chen; Mayun Chen; Hui Cai; Lin Zhang
Journal:  BMC Infect Dis       Date:  2018-08-10       Impact factor: 3.090

6.  Effects of cotrimoxazole prophylaxis on Talaromyces marneffei infection in HIV/AIDS patients receiving antiretroviral therapy: a retrospective cohort study.

Authors:  Junjun Jiang; Fengxiang Qin; Sirun Meng; Eric J Nehl; Jinping Huang; Yanfen Liu; Jun Zou; Wenyi Dong; Jiegang Huang; Hui Chen; Ning Zang; Bingyu Liang; Chuanyi Ning; Yanyan Liao; Chaolian Luo; Huifang Liu; Xin Liu; Jian Wang; Oulu Zhou; Thuy Le; Li Ye; Fengyao Wu; Hao Liang
Journal:  Emerg Microbes Infect       Date:  2019       Impact factor: 7.163

7.  Comparison of pleural effusion features and biomarkers between talaromycosis and tuberculosis in non-human immunodeficiency virus-infected patients.

Authors:  Ye Qiu; Wen Zeng; Hui Zhang; Xiaoning Zhong; Shudan Tang; Jianquan Zhang
Journal:  BMC Infect Dis       Date:  2019-08-27       Impact factor: 3.090

Review 8.  Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients.

Authors:  Jasper F W Chan; Susanna K P Lau; Kwok-Yung Yuen; Patrick C Y Woo
Journal:  Emerg Microbes Infect       Date:  2016-03-09       Impact factor: 7.163

9.  A mass in the upper abdomen derived from Talaromyces marneffei infected lymphadenopathy: a case report.

Authors:  Xue Chen; Lin Jia; Yongfeng Wu; Jing Chang; Tong Zhang; Yingmin Ma; Yulin Zhang
Journal:  BMC Infect Dis       Date:  2021-08-04       Impact factor: 3.090

10.  Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma.

Authors:  Ha Thuc Ai Hien; Tran Tan Thanh; Nguyen Thi Mai Thu; Ashley Nguyen; Nguyen Tat Thanh; Nguyen Phu Huong Lan; Cameron Simmons; Cecilia Shikuma; Nguyen Van Vinh Chau; Guy Thwaites; Thuy Le
Journal:  Mycoses       Date:  2016-07-25       Impact factor: 4.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.